title: Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer.
abstract: To assess the role of docetaxel plus androgen deprivation in metastatic, hormone- sensitive prostate cancer.
  
  
  
  A qualitative systematic review of literature was performed. All the randomized phase III trials comparing docetaxel plus androgen deprivation with androgen deprivation alone in patients with metastatic, hormone-sensitive prostate cancer were considered eligible and included into the analysis.
  
  
  
  Six papers (3 randomized clinical trials, and 3 systematic reviews with meta-analysis) were considered eligible and included into the analysis. A significant improvement in time to progression and OS in the entire population treated with docetaxel plus androgen deprivation was reported in all the trials and meta-analyses, and in two trials and all meta-analyses, respectively. One trial reported improvement of OS only in patients with high volume disease, and the meta-analysis that also analyzed the subgroups of patients with high or low volume disease reported a benefit of docetaxel plus androgen deprivation for either the entire population or the two subgroups of patients.
  
  
  
  The early use of docetaxel combined with androgen deprivation improves the main outcomes in the treatment of metastatic, hormone-sensitive prostate cancer. The available data suggest that docetaxel plus androgen deprivation could be considered the novel standard for fit patients with metastatic, hormone-sensitive prostate cancer.
authors.affiliation: Department of Oncology, City Hospital, Rimini, c.p.n. 35, 47822 Santarcangelo di Romagna (RN), Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Tassinari
authors.forename: Emiliano
authors.initials: E
authors.lastname: Tamburini
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Gianni
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Drudi
authors.forename: Manuela
authors.initials: M
authors.lastname: Fantini
authors.forename: Carlotta
authors.initials: C
authors.lastname: Santelmo
authors.forename: Lucia
authors.initials: L
authors.lastname: Stocchi
authors.forename: Francesco
authors.initials: F
authors.lastname: Montanari
authors.forename: Sergio
authors.initials: S
authors.lastname: Sartori
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D000077143:Docetaxel; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel